Part D Drug Discount Data Is Not Commercial Tool, CMS' Blum Says
Executive Summary
The Centers for Medicaid and Medicare Services is wary about drug industry requests for detailed, claims-level information to support invoices on the drug discounts given to Medicare Part D beneficiaries who have reached the coverage gap
You may also be interested in...
Annual Biopharma Fee Estimates Need More Transparency, BIO Says
The biopharmaceutical industry is pushing for greater transparency around the data used by the federal government to generate preliminary estimates of the market-based fees owed to the government by individual manufacturers and importers in 2011.
Annual Biopharma Fee Estimates Need More Transparency, BIO Says
The biopharmaceutical industry is pushing for greater transparency around the data used by the federal government to generate preliminary estimates of the market-based fees owed to the government by individual manufacturers and importers in 2011.
Orphan Drug “Improvements” May Be Undercut By New Market Share Fees
The Treasury Department’s plans for implementing the branded drug market share fee program mandated by the Affordable Care Act have raised concerns that investment in orphan drug development could be discouraged by a “narrow” reading of the law.